Source: CancerNetwork, May 2025
Combination vs Monotherapy Considerations
Key Discussion Points:
- Phase 3 clinical trials have confirmed superiority of dual immunotherapy over monotherapy in metastatic melanoma
- Patient-specific factors including comorbidities, disease burden, and LDH levels guide therapy selection
- Certain patient populations may still benefit from PD-1 monotherapy over combination approaches